{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:56:01Z","timestamp":1791860161313,"version":"4.3.4"},"reference-count":179,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic driver capable of initiating and maintaining the disease. Despite the remarkable efficacy of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1, some patients may not respond (primary resistance) or may relapse after an initial response (secondary resistance). In a small proportion of cases, development of resistance is accompanied or shortly followed by progression from chronic to blastic phase (BP), characterized by a dismal prognosis. Evolution from CP into BP is a multifactorial and probably multistep phenomenon. Increase in BCR-ABL1 transcript levels is thought to promote the onset of secondary chromosomal or genetic defects, induce differentiation arrest, perturb RNA transcription, editing and translation that together with epigenetic and metabolic changes may ultimately lead to the expansion of highly proliferating, differentiation-arrested malignant cells. A multitude of studies over the past two decades have investigated the mechanisms underlying the closely intertwined phenomena of drug resistance and disease progression. Here, we provide an update on what is currently known on the mechanisms underlying progression and present the latest acquisitions on BCR-ABL1-independent resistance and leukemia stem cell persistence.<\/jats:p>","DOI":"10.3390\/ijms20246141","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T11:16:23Z","timestamp":1575544583000},"page":"6141","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update"],"prefix":"10.3390","volume":"20","author":[{"given":"Luana","family":"Bavaro","sequence":"first","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Hematology\/Oncology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Martelli","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Hematology\/Oncology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Hematology\/Oncology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Hematology\/Oncology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/leu.2008.392","article-title":"The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence","volume":"23","author":"Bruns","year":"2009","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0165-4608(93)90206-2","article-title":"Comparison of clinical and biologic features between myeloid and lymphoid transformation of Philadelphia chromosome positive chronic myeloid leukemia","volume":"71","author":"Tien","year":"1993","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_5","unstructured":"Jaffe, E.S., Harris., N.L., Stein, H., and Vardiman, J.W. (2001). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, WHO Classification of Tumours, IARC Press. [3rd ed.]."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.leukres.2008.07.019","article-title":"Phenotype of blasts in chronic myeloid leukemia in blastic phase\u2014Analysis of bone marrow trephine biopsies and correlation with cytogenetics","volume":"33","author":"Reid","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/ajcp\/107.2.168","article-title":"T-cell blast crisis in chronic myelogenous leukemia: Immunophenotypic and molecular biologic findings","volume":"107","author":"Dorfman","year":"1997","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.leu.2402813","article-title":"Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"17","author":"Schoch","year":"2003","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000099548","article-title":"Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment","volume":"117","author":"Gozzetti","year":"2007","journal-title":"Acta Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4274\/tjh.2014.0211","article-title":"Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia during Imatinib Treatment","volume":"32","author":"Angriman","year":"2015","journal-title":"Turk. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte\u2013macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17967","DOI":"10.1073\/pnas.0808303105","article-title":"BCR-ABL-transformed GMP as myeloid leukemic stem cells","volume":"105","author":"Minami","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/blood-2009-05-222836","article-title":"Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia","volume":"115","author":"Nakahara","year":"2010","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI116786","article-title":"Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation","volume":"92","author":"Wetzler","year":"1993","journal-title":"J. Clin. Invest."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood.V86.6.2371.bloodjournal8662371","article-title":"Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression","volume":"86","author":"Gaiger","year":"1995","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s002770000169","article-title":"The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage","volume":"79","author":"Elmaagacli","year":"2000","journal-title":"Ann. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/gcc.20303","article-title":"Genomewide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high-resolution array-based comparative genomic hybridization","volume":"45","author":"Hosoya","year":"2006","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/gcc.20487","article-title":"Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression","volume":"46","author":"Brazma","year":"2007","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2009-03-210377","article-title":"SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations","volume":"115","author":"Nowak","year":"2010","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s12185-011-0796-9","article-title":"Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate","volume":"93","author":"Nadarajan","year":"2011","journal-title":"Int. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.leukres.2011.12.021","article-title":"Sequential array comparative genomic hybridization analysis identifies copy number changes during blastic transformation of chronic myeloid leukemia","volume":"36","author":"Lee","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/bjh.12850","article-title":"DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia","volume":"166","author":"Krumbholz","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_28","first-page":"1","article-title":"Reactive oxygen species in BCR-ABL1-expressing cells\u2013relevance to chronic myeloid leukemia","volume":"64","author":"Pawlowska","year":"2017","journal-title":"Acta Biochim. Pol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"24273","DOI":"10.1074\/jbc.M002094200","article-title":"The BCR\/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells","volume":"275","author":"Sattler","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance","volume":"108","author":"Koptyra","year":"2006","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2004-05-1941","article-title":"BCR\/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species\u2013dependent DNA double-strand breaks","volume":"104","author":"Nowicki","year":"2004","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0027-5107(01)00167-1","article-title":"Genomic integrity and the repair of double-strand DNA breaks","volume":"480","author":"Pastink","year":"2001","journal-title":"Mutat. Res. Mol. Mech. Mutagen."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1182\/blood-2002-10-3011","article-title":"Down-regulation of BRCA1 in BCR-ABL\u2013expressing hematopoietic cells","volume":"101","author":"Deutsch","year":"2003","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.4161\/15384101.2014.965013","article-title":"Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation","volume":"13","author":"Wolczyk","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.exphem.2015.04.013","article-title":"The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia","volume":"43","author":"Dkhissi","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"10512","DOI":"10.1074\/jbc.TM117.000374","article-title":"Nonhomologous DNA end-joining for repair of DNA double-strand breaks","volume":"293","author":"Pannunzio","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood-2007-07-104257","article-title":"Up-regulation of WRN and DNA ligase III\u03b1 in chronic myeloid leukemia: Consequences for the repair of DNA double-strand breaks","volume":"112","author":"Sallmyr","year":"2008","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/0008-5472.CAN-10-1066","article-title":"BCR\/ABL stimulates WRN to promote survival and genomic instability","volume":"71","author":"Slupianek","year":"2011","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood.V83.12.3449.3449","article-title":"Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia [see comments]","volume":"83","author":"Wada","year":"1994","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/leu.2012.294","article-title":"BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability","volume":"27","author":"Slupianek","year":"2013","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajh.24943","article-title":"Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors","volume":"93","author":"Alhuraiji","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V66.6.1326.1326","article-title":"Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival","volume":"66","author":"Kantarjian","year":"1985","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1182\/blood.V72.1.294.294","article-title":"Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia","volume":"72","author":"Sokal","year":"1988","journal-title":"Blood"},{"key":"ref_44","first-page":"260","article-title":"Chronic myeloid leukemia in chronic phase responding to imatinib: The occurrence of additional cytogenetic abnormalities predicts disease progression","volume":"88","author":"Marktel","year":"2003","journal-title":"Haematologica"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0165-4608(83)90028-6","article-title":"A summary of cytogenetic studies on 534 cases of chronic myelocytic leukemia in Japan","volume":"9","author":"Ishihara","year":"1983","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0165-4608(85)90041-X","article-title":"Karyotypic evolution in Ph-positive chronic myeloid leukemia in relation to management and disease progression","volume":"18","author":"Swolin","year":"1985","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_47","first-page":"974","article-title":"Sequential karyotype study on Ph-positive chronic myelocytic leukemia. Significance of additional chromosomal abnormalities during disease evolution","volume":"60","author":"Krulik","year":"1987","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ijc.2910180105","article-title":"Non-random karyotypic evolution in chronic myeloid leukemia","volume":"18","author":"Mitelman","year":"1976","journal-title":"Int. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/10428199309047856","article-title":"The cytogenetic scenario of chronic myeloid leukemia","volume":"11","author":"Mitelman","year":"1993","journal-title":"Leuk. Lymphoma"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2009.019109","article-title":"Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy","volume":"95","author":"Lippert","year":"2010","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","article-title":"Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis","volume":"120","author":"Luatti","year":"2012","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.gene.2018.11.005","article-title":"Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia","volume":"686","author":"Chandran","year":"2019","journal-title":"Gene"},{"key":"ref_56","first-page":"1134","article-title":"Aberrant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-\u03b1","volume":"10","author":"Johansson","year":"1996","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2141.1995.tb05358.x","article-title":"Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia","volume":"91","author":"Serra","year":"1995","journal-title":"Br. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J. Clin. Invest."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.leukres.2007.08.008","article-title":"Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis","volume":"32","author":"Stagno","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor\u2013resistant CML: Frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood-2018-99-117166","article-title":"Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing","volume":"132","author":"Soverini","year":"2018","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.1073\/pnas.86.17.6783","article-title":"Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia","volume":"86","author":"Ahuja","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.1073\/pnas.88.14.6293","article-title":"p53 in chronic myelogenous leukemia in acute phase","volume":"88","author":"Feinstein","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"13137","DOI":"10.1073\/pnas.93.23.13137","article-title":"Blastic transformation of p53-deficient bone marrow cells by p210bcr\/abl tyrosine kinase","volume":"93","author":"Skorski","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.V95.4.1144.004k04_1144_1150","article-title":"Acquired loss of p53 induces blastic transformation in p210 bcr\/abl-expressing hematopoietic cells: A transgenic study for blast crisis of human CML","volume":"95","author":"Honda","year":"2000","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1073\/pnas.0602402103","article-title":"Loss of p53 impedes the antileukemic response to BCR-ABL inhibition","volume":"103","author":"Wendel","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1182\/blood.V78.12.3259.3259","article-title":"Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia","volume":"78","author":"Ahuja","year":"1991","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/10428190009059278","article-title":"Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia","volume":"38","author":"Beck","year":"2000","journal-title":"Leuk. Lymphoma"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-07-102533","article-title":"RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance","volume":"111","author":"Deluche","year":"2008","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2011-08-370981","article-title":"Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia","volume":"119","author":"Zhao","year":"2012","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.V76.12.2594.2594","article-title":"t (3; 21)(q26; q22): A recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia","volume":"76","author":"Rubin","year":"1990","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1073\/pnas.91.9.4004","article-title":"Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3; 21)(q26; q22) translocations","volume":"91","author":"Nucifora","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V86.1.1.bloodjournal8611","article-title":"AML1 and the 8; 21 and 3; 21 translocations in acute and chronic myeloid leukemia","volume":"86","author":"Nucifora","year":"1995","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","article-title":"Clinical, molecular, and prognostic significance of WHO type inv (3)(q21q26. 2)\/t (3; 3)(q21; q26. 2) and various other 3q abnormalities in acute myeloid leukemia","volume":"28","author":"Lugthart","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bjh.12726","article-title":"Single-cell gene expression analysis reveals clonal architecture of blast-phase chronic myeloid leukaemia","volume":"165","author":"Nukina","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.stem.2008.06.002","article-title":"Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells","volume":"3","author":"Goyama","year":"2008","journal-title":"Cell Stem Cell"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Shen, L., Zhu, J., Chen, F., Lin, W., Cai, J., Zhong, J., and Zhong, H. (2015). RUNX1-Evi-1 fusion gene inhibited differentiation and apoptosis in myelopoiesis: An in vivo study. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1961-y"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood.V85.8.2013.bloodjournal8582013","article-title":"Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia","volume":"85","author":"Sill","year":"1995","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0301-472X(02)01075-5","article-title":"Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: A sequential study in 42 patients","volume":"31","author":"Cervantes","year":"2003","journal-title":"Exp. Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1101\/sqb.2008.73.039","article-title":"The INK4-ARF (CDKN2A\/B) Locus in Hematopoiesis and BCR-ABL\u2013induced Leukemias","volume":"Volume 73","author":"Williams","year":"2008","journal-title":"Cold Spring Harbor Symposia on Quantitative Biology"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Nacheva, E.P., Brazma, D., Virgili, A., Howard-Reeves, J., Chanalaris, A., Gancheva, K., Apostolova, M., Valga\u00f1on, M., Mazzullo, H., and Grace, C. (2010). Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia. BMC Genomics, 11.","DOI":"10.1186\/1471-2164-11-41"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00277-011-1195-2","article-title":"Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der (9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia","volume":"90","author":"Huh","year":"2011","journal-title":"Ann. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR\u2013ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.1439790","article-title":"Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment","volume":"258","author":"Georgopoulos","year":"1992","journal-title":"Science"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4049\/jimmunol.156.2.585","article-title":"The Ikaros gene encodes a family of lymphocyte-restricted zinc finger DNA binding proteins, highly conserved in human and mouse","volume":"156","author":"Wu","year":"1996","journal-title":"J. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.1999.17.12.3753","article-title":"Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia","volume":"17","author":"Sun","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood-2007-09-112631","article-title":"Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: Implications for a new mechanism of resistance","volume":"112","author":"Iacobucci","year":"2008","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1038\/leu.2014.99","article-title":"Ikaros transcripts Ik6\/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation","volume":"28","author":"Wang","year":"2014","journal-title":"Leukemia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/leu.2010.236","article-title":"IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis","volume":"25","author":"Soverini","year":"2011","journal-title":"Leukemia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","article-title":"CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"Makishima","year":"2011","journal-title":"Blood"},{"key":"ref_95","first-page":"179937","article-title":"De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways","volume":"2017","author":"Magistroni","year":"2019","journal-title":"Haematologica"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/bj3530417","article-title":"Protein phosphatase 2A: A highly regulated family of serine\/threonine phosphatases implicated in cell growth and signalling","volume":"353","author":"Janssens","year":"2001","journal-title":"Biochem. J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ng791","article-title":"BCR-ABL suppresses C\/EBP\u03b1 expression through inhibitory action of hnRNP E2","volume":"30","author":"Perrotti","year":"2002","journal-title":"Nat. Genet."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1128\/MCB.18.7.4301","article-title":"CCAAT\/enhancer binding protein \u03b1 is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors","volume":"18","author":"Radomska","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2005-09-3732","article-title":"A MAPK\/HNRPK pathway controls BCR\/ABL oncogenic potential by regulating MYC mRNA translation","volume":"107","author":"Notari","year":"2006","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/blood-2007-03-078303","article-title":"High levels of the BCR\/ABL oncoprotein are required for the MAPK-hnRNP-E2\u2013dependent suppression of C\/EBP\u03b1-driven myeloid differentiation","volume":"110","author":"Chang","year":"2007","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.cell.2010.01.007","article-title":"miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts","volume":"140","author":"Eiring","year":"2010","journal-title":"Cell"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1182\/blood.V77.11.2431.2431","article-title":"Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia","volume":"77","author":"Nelkin","year":"1991","journal-title":"Blood"},{"key":"ref_105","first-page":"973","article-title":"The estrogen receptor CpG island is methylated in most hematopoietic neoplasms","volume":"56","author":"Issa","year":"1996","journal-title":"Cancer Res."},{"key":"ref_106","first-page":"1678","article-title":"HIC1 hypermethylation is a late event in hematopoietic neoplasms","volume":"57","author":"Issa","year":"1997","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1182\/blood.V95.9.2990.009k08_2990_2992","article-title":"Quantitative measure of c-abl andp15 methylation in chronic myelogenous leukemia: Biological implications","volume":"95","author":"Nguyen","year":"2000","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1200\/JCO.2003.08.166","article-title":"Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa","volume":"21","author":"Castillejo","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1158\/1078-0432.CCR-07-0919","article-title":"Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis","volume":"13","author":"Strathdee","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Jelinek, J., Gharibyan, V., Estecio, M.R.H., Kondo, K., He, R., Chung, W., Lu, Y., Zhang, N., Liang, S., and Kantarjian, H.M. (2011). Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0022110"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2016.143","article-title":"Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia","volume":"30","author":"Heller","year":"2016","journal-title":"Leukemia"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1535-6108(03)00020-5","article-title":"BCR\/ABL activates mdm2 mRNA translation via the La antigen","volume":"3","author":"Trotta","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1093\/emboj\/17.15.4442","article-title":"TLS\/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR\/ABL-mediated leukemogenesis","volume":"17","author":"Perrotti","year":"1998","journal-title":"EMBO J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1182\/blood-2005-08-3181","article-title":"Inducible activation of CEBPB, a gene negatively regulated by BCR\/ABL, inhibits proliferation and promotes differentiation of BCR\/ABL-expressing cells","volume":"107","author":"Guerzoni","year":"2006","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1182\/blood-2007-05-090472","article-title":"Identification of novel posttranscriptional targets of the BCR\/ABL oncoprotein by ribonomics: Requirement of E2F3 for BCR\/ABL leukemogenesis","volume":"111","author":"Eiring","year":"2008","journal-title":"Blood"},{"key":"ref_116","first-page":"5716","article-title":"Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin","volume":"63","author":"Ly","year":"2003","journal-title":"Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/sj.cdd.4401606","article-title":"BCR\/ABL, mRNA translation and apoptosis","volume":"12","author":"Perrotti","year":"2005","journal-title":"Cell Death Differ."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1073\/pnas.1213021110","article-title":"ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia","volume":"110","author":"Jiang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.stem.2016.05.004","article-title":"ADAR1 activation drives leukemia stem cell self-renewal by impairing Let-7 biogenesis","volume":"19","author":"Zipeto","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12967-014-0370-3","article-title":"An RNA editing fingerprint of cancer stem cell reprogramming","volume":"13","author":"Crews","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.med.59.053006.104707","article-title":"MicroRNAs in cancer","volume":"60","author":"Garzon","year":"2009","journal-title":"Annu. Rev. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.molmed.2006.10.006","article-title":"MicroRNA expression and function in cancer","volume":"12","author":"Garzon","year":"2006","journal-title":"Trends Mol. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13148-018-0587-8","article-title":"The role and mechanisms of action of microRNAs in cancer drug resistance","volume":"11","author":"Si","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-4598-10-41","article-title":"Expression patterns of microRNAs associated with CML phases and their disease related targets","volume":"10","author":"Burda","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.3324\/haematol.2018.193086","article-title":"BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia","volume":"103","author":"Srutova","year":"2018","journal-title":"Haematologica"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature22314","article-title":"Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia","volume":"545","author":"Hattori","year":"2017","journal-title":"Nature"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.tcb.2014.03.003","article-title":"Regulation of mTORC1 by amino acids","volume":"24","author":"Sabatini","year":"2014","journal-title":"Trends Cell Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nature09171","article-title":"Regulation of myeloid leukaemia by the cell-fate determinant Musashi","volume":"466","author":"Ito","year":"2010","journal-title":"Nature"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nm.2187","article-title":"Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia","volume":"16","author":"Kharas","year":"2010","journal-title":"Nat. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_132","first-page":"589","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol. Clin."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: The paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_134","unstructured":"Sundaram, D.N.M., Jiang, X., Brandwein, J.M., Valencia-Serna, J., Remant, K.C., and Uluda\u011f, H. (2019). Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options. Drug Discov. Today."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","article-title":"Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells","volume":"111","author":"Wu","year":"2008","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor\u2013induced cell death in Philadelphia chromosome\u2013positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J. Clin. Invest."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1182\/blood-2011-03-341073","article-title":"SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome\u2013positive cells derived from patients with chronic myeloid leukemia","volume":"118","author":"Esposito","year":"2011","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/onc.2012.83","article-title":"SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL\u2013independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/leu.2014.245","article-title":"Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia","volume":"29","author":"Eiring","year":"2015","journal-title":"Leukemia"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2014-08-588855","article-title":"shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance","volume":"125","author":"Khorashad","year":"2015","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2013-04-495374","article-title":"Preclinical and Clinical Efficacy of XPO1\/CRM1 Inhibition by the Karyopherin Inhibitor KPT-330 in Ph+ Leukemias","volume":"122","author":"Walker","year":"2013","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"201","DOI":"10.18632\/genesandcancer.111","article-title":"Combination of jak2 and hsp90 inhibitors: An effective therapeutic option in drug-resistant chronic myelogenous leukemia","volume":"7","author":"Chakraborty","year":"2016","journal-title":"Genes Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/leu.2016.51","article-title":"A role for FOXO1 in BCR\u2013ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"30","author":"Wagle","year":"2016","journal-title":"Leukemia"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/leu.2017.87","article-title":"Combined inhibition of \u03b2-catenin and Bcr\u2013Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo","volume":"31","author":"Zhou","year":"2017","journal-title":"Leukemia"},{"key":"ref_148","unstructured":"Eiring, A.M., Jonathan, A., Clinton, C.M., Ethan, D., Thomas, H., and Michael, W.D. (2017). Loss of G0S2 in Kinase-Independent TKI Resistance and Blastic Transformation of CML. Am Soc. Hematol., 4173."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1038\/s41388-018-0157-8","article-title":"Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor","volume":"37","author":"Zhu","year":"2018","journal-title":"Oncogene"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"35293","DOI":"10.18632\/oncotarget.9182","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation","volume":"7","author":"Chomel","year":"2016","journal-title":"Oncotarget"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fonc.2018.00194","article-title":"Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission","volume":"30","author":"Bocchia","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"Allan","year":"2007","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J. Clin. Invest."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: Stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1182\/blood-2006-06-032490","article-title":"Role of BCR\/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells","volume":"109","author":"Modi","year":"2007","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2010-08-303495","article-title":"Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib","volume":"119","author":"Kumari","year":"2012","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-\u03b2\u2013FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/stem.1748","article-title":"The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors","volume":"32","author":"Pellicano","year":"2014","journal-title":"Stem Cells"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nature01593","article-title":"A role for Wnt signalling in self-renewal of haematopoietic stem cells","volume":"423","author":"Reya","year":"2003","journal-title":"Nature"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of \u03b2-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nm1489","article-title":"Requirement for CD44 in homing and engraftment of BCR-ABL\u2013expressing leukemic stem cells","volume":"12","author":"Krause","year":"2006","journal-title":"Nat. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2013-11-538694","article-title":"Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche","volume":"123","author":"Krause","year":"2014","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"17468","DOI":"10.1073\/pnas.1111138108","article-title":"Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia","volume":"108","author":"Kuroda","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","article-title":"Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia","volume":"21","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia\u2013specific T cells results in T-cell exhaustion and disease progression","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/cdd.2014.89","article-title":"Regulation of hematopoietic and leukemic stem cells by the immune system","volume":"22","author":"Riether","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2016-09-742049","article-title":"CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression","volume":"129","author":"Tarafdar","year":"2017","journal-title":"Blood"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1182\/blood.V128.22.1219.1219","article-title":"Novel fusion genes at CML diagnosis reveal a complex pattern of genomic rearrangements and sequence inversions associated with the Philadelphia chromosome in patients with early blast crisis","volume":"128","author":"Marum","year":"2016","journal-title":"Blood"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/bloodadvances.2017006825","article-title":"ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure","volume":"1","author":"Marum","year":"2017","journal-title":"Blood Adv."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1182\/blood-2010-08-304477","article-title":"Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression","volume":"117","author":"Lucas","year":"2011","journal-title":"Blood"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/cncr.30490","article-title":"Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study","volume":"123","author":"Rousselot","year":"2017","journal-title":"Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/24\/6141\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:40:38Z","timestamp":1760190038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/24\/6141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":179,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["ijms20246141"],"URL":"https:\/\/doi.org\/10.3390\/ijms20246141","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,5]]}}}